-

Half-Year Liquidity Contract Statement for Valerio Therapeutics

PARIS--(BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entered into between VALERIO THERAPEUTICS (Paris:ALVIO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2024:

- 392,365 shares
- € 144,905.34
- Number of executions on buy side on semester: 108
- Number of executions on sell side on semester: 95
- Traded volume on buy side on semester: 128,013 shares for € 15,133.69
- Traded volume on sell side on semester: 103,822 shares for € 12,955.33

As a reminder:

  • the following resources appeared on the last half year statement on 31 December 2023 on the liquidity account:

- 368,174 shares
- € 144,918.05
- Number of executions on buy side on semester: 324
- Number of executions on sell side on semester: 244
- Traded volume on buy side on semester: 304,205 shares for € 69,976.87
- Traded volume on sell side on semester: 223,191 shares for € 56,117.81

  • the following resources appeared on the liquidity account when the activity started:

- 87,612 shares
- € 196,423.24

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22, 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

Public limited company with a capital of € 21,610,998.20
Registered office: 49 boulevard du Général Martial Valin - 75015 Paris
410 910 095 R.C.S. on the Paris Trade and Companies Register

Contacts

Valerio Therapeutics
Investor Relations
investors@valeriotx.com
tel : +33 (0) 1 70 38 33 99

VALERIO THERAPEUTICS

BOURSE:ALVIO
Release Versions
EnglishFrench

Contacts

Valerio Therapeutics
Investor Relations
investors@valeriotx.com
tel : +33 (0) 1 70 38 33 99

More News From VALERIO THERAPEUTICS

Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors 

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the signing of a definitive share purchase agreement (the "SPA") and of the related contribution agreement (the "Contribution Agreement") for the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"), ba...

Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), provides an update on the contemplated acquisition of 100% of the share capital of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). On July 1, 2026, Valerio announced the submission of a binding offer for the Acquisition on the basis of an enterprise value of EUR 30 million....

Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics (“Valerio” or the “Company”), today announces that it has entered into a binding term-sheet with Abivax SA (“Abivax”), setting out the principal terms of an exclusive worldwide research and development collaboration. The final terms remain subject to the signing of the definitive co-ownership and license agreement....
Back to Newsroom